abrdn plc Acquires Shares of 158,645 Sanofi (NASDAQ:SNY)

abrdn plc acquired a new stake in Sanofi (NASDAQ:SNY) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 158,645 shares of the company’s stock, valued at approximately $7,889,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. HF Advisory Group LLC increased its position in Sanofi by 62.1% in the 4th quarter. HF Advisory Group LLC now owns 20,369 shares of the company’s stock valued at $1,013,000 after acquiring an additional 7,803 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of Sanofi by 3.4% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,541 shares of the company’s stock worth $325,000 after buying an additional 216 shares during the period. DGS Capital Management LLC grew its position in shares of Sanofi by 3.5% during the 4th quarter. DGS Capital Management LLC now owns 10,194 shares of the company’s stock worth $507,000 after buying an additional 345 shares during the period. London & Capital Asset Management Ltd grew its position in shares of Sanofi by 6.0% during the 4th quarter. London & Capital Asset Management Ltd now owns 212,533 shares of the company’s stock worth $10,569,000 after buying an additional 12,089 shares during the period. Finally, Simplicity Solutions LLC grew its position in shares of Sanofi by 27.4% during the 4th quarter. Simplicity Solutions LLC now owns 96,102 shares of the company’s stock worth $4,779,000 after buying an additional 20,662 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Down 0.5 %

Sanofi stock opened at $49.13 on Friday. The company’s 50 day simple moving average is $47.71 and its 200 day simple moving average is $48.41. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $56.26. The firm has a market capitalization of $124.28 billion, a price-to-earnings ratio of 24.69, a PEG ratio of 1.49 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a return on equity of 19.69% and a net margin of 10.52%. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $13.02 billion. As a group, sell-side analysts anticipate that Sanofi will post 4.09 EPS for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. Sanofi’s payout ratio is presently 69.35%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Morgan Stanley initiated coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target for the company. Finally, TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Sanofi has a consensus rating of “Hold” and a consensus price target of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.